ClinicalTrials.gg
CompletedNCT00108017Updated May 13, 2015

Comparison of the Effects of Two Glaucoma Drugs Over 24 Hours (0507A-137)(COMPLETED)

A Phase 3 interventional study of MK0507A, dorzolamide hydrochloride (+) timolol maleate and Comparator: timolol maleate in Glaucoma and Ocular Hypertension, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-05-13.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing timolol in Glaucoma — none open to participants now, none under way, none of them phase 3. Timolol · Glaucoma.

Enrollment
Largest of 28
330 · median 60
Started
2005
the only one that year
Phase 3
5 of 28
none open now
Registered
1st of 28
by date
Lead sponsor
3 of 28
Merck Sharp & Dohme LLC

Among the 28 studies testing timolol in Glaucoma, this one has the largest enrollment, is the only one that started in 2005, is one of 5 in phase 3, and was the 1st registered.

Glaucoma

1,419 studies on the registry are indexed under Glaucoma; 220 are open to participants now.

Browse Glaucoma studies →

Open to participants now

None of the 28 studies testing timolol in Glaucoma is open now. The open studies under Glaucoma, anywhere →

About timolol

Timolol: first FDA approval 1978 (TIMOPTIC), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 28 studies testing timolol in Glaucoma as a file.
02

Study summary

This study is comparing 2 medications for glaucoma and how effective they are at controlling glaucoma over the course of an entire day.

03

Conditions studied

  • Glaucoma
  • Ocular Hypertension

Keywords

  • Ocular hypertension (excessive pressure in the eye)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with glaucoma or ocular hypertension

Exclusion criteria

Exclusion Criteria:

  • Other eye conditions
  • Poor vision
  • Recent eye surgery
  • Use of contact lenses
  • Nursing or pregnant women
  • Use of some other selected medications
  • Drug or alcohol abuse
  • Asthma
  • Slow heart beat
  • Allergy or previous reaction to study drugs
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
330 participants (actual)

Interventions

  • DrugMK0507A, dorzolamide hydrochloride (+) timolol maleate
  • DrugDuration of Treatment: Part 1) 6 wk timolol maleate run in
  • DrugPart 2) 6 wk washout pd Part 3) two 8 wk active tx pds
06

What researchers measure

Primary outcomes

  1. 24 hour diurnal IOP reduction after 8 weeks of treatment

    Time frame: After 8 weeks of treatment

Secondary outcomes

  1. IOP reduction a) from baseline at 6 weeks; b) comparison with timolol; c) comparison day versus night

    Time frame: At 6 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Feldman RM, Stewart RH, Stewart WC, Jia G, Smugar SS, Galet VA. 24-hour control of intraocular pressure with 2% dorzolamide/0.5% timolol fixed-combination ophthalmic solution in open-angle glaucoma. Curr Med Res Opin. 2008 Aug;24(8):2403-12. doi: 10.1185/03007990802243366. Epub 2008 Jul 14. PubMed 18627642 ↗
  • Olander KW, Galet VA, Jia G, Smugar SS, Stewart WC. Relationship between visual field severity and response to fixed combination dorzolamide/timolol or timolol alone. J Ocul Pharmacol Ther. 2009 Aug;25(4):357-64. doi: 10.1089/jop.2008.0104. PubMed 19441888 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2005, a primary completion of Jul 2006 and a completion of Jul 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2005
First posted
Apr 13, 2005
Start
Apr 2005
Primary completionActual
Jul 2006
CompletionActual
Jul 2006
Last update
May 13, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00108017
Responsible party
Sponsor
First posted
Apr 13, 2005
Start date
Apr 2005
Primary completion
Jul 2006
Completion
Jul 2006
Last update
May 13, 2015

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Timolol

Start the discussion